Canaccord Genuity Group started coverage on shares of Niagen Bioscience (NASDAQ:NAGE - Free Report) in a report published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock.
Niagen Bioscience Stock Performance
Niagen Bioscience stock traded down $0.01 during midday trading on Tuesday, reaching $10.81. The stock had a trading volume of 874,277 shares, compared to its average volume of 835,180. The firm has a fifty day moving average of $8.13. Niagen Bioscience has a twelve month low of $2.31 and a twelve month high of $11.16. The firm has a market cap of $851.50 million, a price-to-earnings ratio of 63.59 and a beta of 1.94.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Stories
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
